RNS Number : 4449E Renalytix AI PLC 06 November 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Change of adviser NEW YORK , November 6, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, confirms that the
RNS Number : 9886D Renalytix AI PLC 02 November 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Posting of Annual Report & Accounts and Notice of AGM NEW YORK , November 2, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro
NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its full
RNS Number : 3088D Renalytix AI PLC 27 October 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Full Year Report NEW YORK , October 27, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing
Renalytix AI plc ("RenalytixAI" or the "Company") Notice of results Analyst and Investor presentations NEW YORK , Oct. 16, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management
RNS Number : 2682C Renalytix AI PLC 16 October 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Notice of results Analyst and Investor presentations RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update NEW YORK , October 16,
RNS Number : 9631B Renalytix AI PLC 13 October 2020 Not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or within the United States , Australia , Canada , Hong Kong , Japan , New Zealand , the Republic of South Africa or any other jurisdiction where
RenalytixAI is now currently licensed to provide KidneyIntelX testing services for patients in 49 states NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Renalytix AI, Inc. (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical
RNS Number : 6495Z Renalytix AI PLC 22 September 2020 This announcement contains inside information Renalytix AI plc ("RenalytixAI", the "Company") RenalytixAI Receives California Commercial Laboratory Certification RenalytixAI is now currently licensed to provide KidneyIntelX testing
